Literature DB >> 17875681

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.

Yasser M El-Sherbiny1, Josephine L Meade, Tim D Holmes, Dennis McGonagle, Sarah L Mackie, Ann W Morgan, Gordon Cook, Sylvia Feyler, Stephen J Richards, Faith E Davies, Gareth J Morgan, Graham P Cook.   

Abstract

Recent evidence suggests a role for natural killer (NK) cells in the control of multiple myeloma. We show that expression of the NK cell receptor DNAM-1 (CD226) is reduced on CD56(dim) NK cells from myeloma patients with active disease compared with patients in remission and healthy controls. This suggested that this receptor might play a role in NK-myeloma interactions. The DNAM-1 ligands Nectin-2 (CD112) and the poliovirus receptor (PVR; CD155) were expressed by most patient myeloma samples analyzed. NK killing of patient-derived myelomas expressing PVR and/or Nectin-2 was DNAM-1 dependent, revealing a functional role for DNAM-1 in myeloma cell killing. In myeloma cell lines, cell surface expression of PVR was associated with low levels of NKG2D ligands, whereas cells expressing high levels of NKG2D ligands did not express PVR protein or mRNA. Furthermore, NK cell-mediated killing of myeloma cell lines was dependent on either DNAM-1 or NKG2D but not both molecules. In contrast, the natural cytotoxicity receptor NKp46 was required for the killing of all myeloma cell lines analyzed. Thus, DNAM-1 is important in the NK cell-mediated killing of myeloma cells expressing the cognate ligands. The importance of NKp46, NKG2D, and DNAM-1 in myeloma killing mirrors the differential expression of NK cell ligands by myeloma cells, reflecting immune selection during myeloma disease progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875681     DOI: 10.1158/0008-5472.CAN-06-4230

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  129 in total

1.  Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.

Authors:  Sebastian Seth; Quan Qiu; Simon Danisch; Michael K Maier; Asolina Braun; Inga Ravens; Niklas Czeloth; Rebecca Hyde; Oliver Dittrich-Breiholz; Reinhold Förster; Günter Bernhardt
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Authors:  Giulia Matusali; Marina Potestà; Angela Santoni; Cristina Cerboni; Margherita Doria
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.

Authors:  Brenna E Swift; Brent A Williams; Yoko Kosaka; Xing-Hua Wang; Jeffrey A Medin; Sowmya Viswanathan; Joaquin Martinez-Lopez; Armand Keating
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 4.  Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Authors:  James O J Davies; Kate Stringaris; A John Barrett; Katayoun Rezvani
Journal:  Cytotherapy       Date:  2014-05-20       Impact factor: 5.414

5.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.

Authors:  Noa Stanietsky; Hrvoje Simic; Jurica Arapovic; Amir Toporik; Ofer Levy; Amit Novik; Zurit Levine; Meirav Beiman; Liat Dassa; Hagit Achdout; Noam Stern-Ginossar; Pinhas Tsukerman; Stipan Jonjic; Ofer Mandelboim
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-07       Impact factor: 11.205

6.  Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma.

Authors:  M Karabulut; M Gunaldi; H Alis; C U Afsar; S Karabulut; M Serilmez; C Akarsu; H Seyit; N F Aykan
Journal:  Clin Transl Oncol       Date:  2015-07-17       Impact factor: 3.405

Review 7.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 8.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

9.  Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients.

Authors:  Zhuwei Xu; Tao Zhang; Ran Zhuang; Yun Zhang; Wei Jia; Chaojun Song; Kun Yang; Angang Yang; Boquan Jin
Journal:  BMC Immunol       Date:  2009-06-02       Impact factor: 3.615

10.  Accelerated tumor growth in mice deficient in DNAM-1 receptor.

Authors:  Akiko Iguchi-Manaka; Hirayasu Kai; Yumi Yamashita; Kai Shibata; Satoko Tahara-Hanaoka; Shin-ichiro Honda; Teruhito Yasui; Hitoshi Kikutani; Kazuko Shibuya; Akira Shibuya
Journal:  J Exp Med       Date:  2008-11-24       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.